Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study.
Low-sodium
Peritoneal Dialysis
Resistant hypertension
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
08 05 2021
08 05 2021
Historique:
received:
15
03
2021
accepted:
29
04
2021
entrez:
9
5
2021
pubmed:
10
5
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging. This is a case-study reporting two consecutive ESKD patients treated by a novel peritoneal PD solution with a mildly reduced sodium content (130 mmol/L) to treat hypertension. In the first case, a 78-year-old woman treated by Continuous Ambulatory PD (CAPD) with standard solution (three 4 h-dwells per day 1.36% glucose 132 mmol/L) showed resistant hypertension confirmed by ambulatory blood pressure monitoring (ABPM), reporting 24 h-BP: 152/81 mmHg, day-BP:151/83 mmHg and night-ABP: 153/75 mmHg, with inversion of the circadian systolic BP rhythm (1.01), despite use of three anti-hypertensives and a diuretic at adequate doses. No sign of hypervolemia was evident. We then switched from standard PD to low-sodium solution in all daily dwells. A six-months low-sodium CAPD enabled us to reduce diurnal (134/75 mmHg) and nocturnal BP (122/67 mmHg), restoring the circadian BP rhythm, with no change in ultrafiltration or residual diuresis. Diet and drug prescription were unmodified too. The second case was a 61-year-old woman in standard CAPD (three 5 h-dwells per day) suffering from hypertension confirmed by ABPM (mean 24 h-ABP: 139/84 mmHg; mean day-ABP:144/88 mmHg and mean night-ABP:124/70 mmHg). She was switched from 132-Na CAPD to 130-Na CAPD, not changing dialysis schedule. No fluid expansion was evident. During low-sodium CAPD, antihypertensive therapy (amlodipine 10 mg and Olmesartan 20 mg) has been reduced until complete suspension. After 6 months, we repeated ABPM showing a substantial reduction in mean 24 h-ABP (117/69 mmHg), mean diurnal ABP (119/75 mmHg) and mean nocturnal ABP (111/70 mmHg). Ultrafiltration and residual diuresis remained unmodified. No side effects were reported in either cases. This case-report study suggests that mild low-sodium CAPD might reduce BP in hypertensive ESKD patients.
Identifiants
pubmed: 33964894
doi: 10.1186/s12882-021-02380-4
pii: 10.1186/s12882-021-02380-4
pmc: PMC8105985
doi:
Substances chimiques
Dialysis Solutions
0
Sodium
9NEZ333N27
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Références
Circulation. 1999 Oct 12;100(15):1635-8
pubmed: 10517735
J Nephrol. 2020 Feb;33(1):59-68
pubmed: 31734929
Hypertens Res. 2010 Jun;33(6):515-20
pubmed: 20379191
J Nephrol. 2019 Apr;32(2):231-239
pubmed: 29978446
Perit Dial Int. 2020 Sep;40(5):446-454
pubmed: 32425111
J Nephrol. 2021 Apr;34(2):503-519
pubmed: 32767274
J Hypertens. 2020 Nov;38(11):2252-2260
pubmed: 32618891
Am J Kidney Dis. 2016 May;67(5):753-61
pubmed: 26388284
Nephrol Dial Transplant. 2020 Apr 06;:
pubmed: 32252091
Kidney Int. 2015 Feb;87(2):434-41
pubmed: 25100048
Nephrol Dial Transplant. 2013 Oct;28(10):2620-8
pubmed: 24078645
Circulation. 1997 Sep 16;96(6):1859-62
pubmed: 9323073
Perit Dial Int. 2019 Jul-Aug;39(4):335-343
pubmed: 31123069
Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640
pubmed: 28340239
Kidney Int. 2018 Aug;94(2):419-429
pubmed: 29776755
J Am Soc Nephrol. 2017 Aug;28(8):2491-2497
pubmed: 28473637
J Am Soc Nephrol. 2017 Jun;28(6):1867-1876
pubmed: 28154199
Nephrol Dial Transplant. 1999 Jun;14(6):1536-40
pubmed: 10383021
Kidney Int. 1995 Dec;48(6):1959-66
pubmed: 8587258
Drugs. 2003;63(19):2079-105
pubmed: 12962523
Int J Hypertens. 2013;2013:929183
pubmed: 23710342
Nephrol Dial Transplant. 2009 May;24(5):1609-17
pubmed: 19145002